The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | CAR T-cell therapy: the patient’s perspective
Bregje Verhoeven, from the European Society for Blood & Marrow Transplantation (EBMT), Amsterdam, Netherlands, gives an insight as to the patient perspective of CAR T-cell therapy. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Ms Verhoeven gives advice to both the patients and institutions involved. This meeting was co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
